The Financial Times reported on Aug. 2 that Bristol-Myers Squibb and AstraZeneca are in discussions with regard to a possible merger. Astra shares fell 8% and Bristol shares were down about 1% in early trading on Aug. 3.
Bristol is launching innovative drugs in cardiology and neurology, which should have strong sales trajectories, given the high unmet medical need.
The acquisition of Celgene came shortly before the start of generic competition for that firm's cancer drug Revlimid in 2022, setting up a major growth obstacle over several years, given the planned staggered generic entry.
|
Metric
|
BMY
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.29 | 46.83 | 10.47 |
Price/Book Value | 6.11 | 8.85 | 4.27 |
Price/Sales | 2.78 | 5.60 | 2.29 |
Price/Cash Flow | 9.20 | 16.83 | 9.78 |
|
Metric
|
BMY
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 1.29 | 0.71 | 0.52 |
Current Ratio | 1.53 | 1.32 | 0.82 |
Interest Coverage | 7.88 | 4.28 | 9.51 |
|
Metric
|
BMY
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | 14.59% | 6.27% | 11.66% |
Return on Equity (Normalized) | 68.67% | 16.68% | 42.98% |
Return on Invested Capital (Normalized) | 21.69% | 9.82% | 22.63% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|wZpY&MjQ | LOCK|?#b | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|d?hBz>Y | LOCK|&PS | $663B | |||
| AbbVie Inc
ABBV
| LOCK|$T!hMm | LOCK|h& | $453B | |||
| Merck & Co Inc
MRK
| LOCK|sR#$?># | LOCK|r$< | $371B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|%Vr$<r%Y | LOCK|y^d | $353B | |||
| Novartis AG ADR
NVS
| LOCK|&&?V!j% | LOCK|mx^ | $305B | |||
| AstraZeneca PLC
AZN
| LOCK|#S&^M&N | LOCK|rDW | $252B | |||
| Amgen Inc
AMGN
| LOCK|<<CW>@M@ | LOCK|$> | $236B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|!?lq%bk | LOCK|z@ | $206B | |||
| Gilead Sciences Inc
GILD
| LOCK|&$t>>m# | LOCK|?C | $187B |
United States